Dynatronics (DYNT)

Dynatronics is a leading medical device company committed to providing high-quality restorative products designed to accelerate achieving optimal health. The Company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and consumers. The Company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin®, Solaris™, Hausmann™, Physician's Choice®, and PROTEAM™, among others.

Company profile

Ticker

DYNT

Exchange

NASDAQ

Website

www.dynatronics.com

CEO

John A. Krier

Incorporated

Utah

Location

Utah

Fiscal year end

Jun 30

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Hill-Rom • Nuvasive • Integra Lifesciences ...

Former names

DYNATRONICS LASER CORP

SEC CIK

0000720875

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Dynatronics Distribution Co. LLC • Hausmann Enterprises, LLC • Dynatronics Medical Products, LLC • Bird & Cronin, LLC ...

IRS number

870398434

DYNT stock data

1M 1Y 5Y

News

From Benzinga Pro

Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2022

27 Jul 22

Lake Street Initiates Coverage On Dynatronics with Buy Rating, Announces Price Target of $4

27 Jul 22

Lake Street analyst Brooks O'Neil initiates coverage on Dynatronics (NASDAQ:DYNT) with a Buy rating and announces Price Target of $4.

Dynatronics's Return On Capital Employed Insights

17 Jun 22

Dynatronics (NASDAQ:DYNT) brought in sales totaling $10.32 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 2.1%, resulting in a loss of $1.47 million.

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

12 May 22

12 Aug 22

30 Jun 23

Financial summary

Financial statements Chart DYNT financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jun 21	Jun 20	Jun 19	Jun 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.47M	2.47M	2.47M	2.47M	2.47M	2.47M
Cash burn (monthly)	366.86K	181.51K	478.51K	(no burn)	(no burn)	(no burn)
Cash used (since last report)	1.61M	798.57K	2.11M	n/a	n/a	n/a
Cash remaining	858.8K	1.67M	367.58K	n/a	n/a	n/a
Runway (months of cash)	2.3	9.2	0.8	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from Dynatronics earnings reports.

Recent insider trades

DYNT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
21 Jul 22	Norman Roegner III	Common Stock	Grant	Acquire A	No	No	0.64	15,180	9.72K	24,472
8 Jul 22	John Anthony Krier	Common Stock	Grant	Acquire A	No	No	0.63	12,500	7.88K	47,322
7 Jul 22	Baker Brian D.	Common Stock	Other	Acquire J	No	No	0	8,550	0	127,623
7 Jul 22	Essig Stuart	Common Stock	Grant	Acquire A	Yes	No	0	5,000	0	110,601
7 Jul 22	Essig Stuart	Common Stock	Other	Acquire J	Yes	No	0	20,376	0	258,474
7 Jul 22	Essig Stuart	Common Stock	Other	Acquire J	No	No	0	101,520	0	1,853,503
7 Jul 22	Enright Erin S.	Common Stock	Grant	Acquire A	No	No	0	5,000	0	110,601
7 Jul 22	Enright Erin S.	Common Stock	Other	Acquire J	Yes	No	0	20,378	0	258,474
7 Jul 22	Enright Erin S.	Common Stock	Other	Acquire J	Yes	No	0	101,520	0	1,853,503

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

DYNT institutional ownership history Ownership history

8.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	14	20	-30.0%
Opened positions	1	2	-50.0%
Closed positions	7	2	+250.0%
Increased positions	2	6	-66.7%
Reduced positions	5	6	-16.7%

13F shares	Current	Prev Q	Change
Total value	1.07M	3.49M	-69.3%
Total shares	1.48M	3.49M	-57.7%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Renaissance Technologies	1.03M	$748K	-6.2%
Vanguard	106.19K	$77K	0.0%
Albion Financial	90K	$65K	0.0%
Advisor	82.08K	$60K	+6.5%
Geode Capital Management	61.16K	$44K	0.0%
BAC Bank Of America	20K	$15K	-0.0%
BLK Blackrock	18.48K	$13K	0.0%
HRT Financial	16.98K	$12K	NEW
Squarepoint Ops	15.7K	$11K	-13.8%
Two Sigma Advisers	11.1K	$8K	-68.9%

Largest transactions	Shares	Bought/sold	Change
Armistice Capital	0	-1.63M	EXIT
Perritt Capital Management	0	-200K	EXIT
Millennium Management	0	-70.41K	EXIT
Renaissance Technologies	1.03M	-67.7K	-6.2%
Two Sigma Advisers	11.1K	-24.6K	-68.9%
HRT Financial	16.98K	+16.98K	NEW
Citadel Advisors	0	-15.86K	EXIT
Acadian Asset Management	0	-13K	EXIT
Two Sigma Securities	0	-10.3K	EXIT
Advisor	82.08K	+5K	+6.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Management Discussion

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
We design, manufacture, and sell a broad range of restorative products for clinical use in physical therapy, rehabilitation, orthopedics, pain management, and athletic training. Through our distribution channels, we market and sell to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals.